ADAPTIMMUNE THERAPEUTICS-ADR (ADAP)
US00653A1079 - ADR
ADAP gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. ADAP may be in some trouble as it scores bad on both profitability and health. ADAP is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ADAP has reported negative net income.
ADAP had a negative operating cash flow in the past year.
ADAP had negative earnings in each of the past 5 years.
ADAP had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
ADAP has a Return On Assets of -22.54%. This is in the better half of the industry: ADAP outperforms 75.58% of its industry peers.
Looking at the Return On Equity, with a value of -75.30%, ADAP is in line with its industry, outperforming 54.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.54% | ||
| ROE | -75.3% | ||
| ROIC | N/A |
ROA(3y)-41.42%
ROA(5y)-45.74%
ROE(3y)-188.98%
ROE(5y)-143.21%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ADAP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ADAP does not have a ROIC to compare to the WACC, probably because it is not profitable.
ADAP has more shares outstanding than it did 1 year ago.
ADAP has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ADAP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -3.56, we must say that ADAP is in the distress zone and has some risk of bankruptcy.
ADAP has a Altman-Z score of -3.56. This is comparable to the rest of the industry: ADAP outperforms 45.81% of its industry peers.
ADAP has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
ADAP has a Debt to Equity ratio of 0.26. This is in the lower half of the industry: ADAP underperforms 69.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.56 |
ROIC/WACCN/A
WACC8.84%
2.3 Liquidity
A Current Ratio of 3.09 indicates that ADAP has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.09, ADAP is doing worse than 62.92% of the companies in the same industry.
A Quick Ratio of 3.09 indicates that ADAP has no problem at all paying its short term obligations.
ADAP's Quick ratio of 3.09 is on the low side compared to the rest of the industry. ADAP is outperformed by 60.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.09 | ||
| Quick Ratio | 3.09 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 40.99% over the past year.
Looking at the last year, ADAP shows a very strong growth in Revenue. The Revenue has grown by 99.89%.
Measured over the past years, ADAP shows a small growth in Revenue. The Revenue has been growing by 0.26% on average per year.
EPS 1Y (TTM)40.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%204.35%
Revenue 1Y (TTM)99.89%
Revenue growth 3Y147.83%
Revenue growth 5Y0.26%
Sales Q2Q%2399.63%
3.2 Future
The Earnings Per Share is expected to grow by 1.81% on average over the next years.
The Revenue is expected to grow by 18.81% on average over the next years. This is quite good.
EPS Next Y40.09%
EPS Next 2Y18.76%
EPS Next 3Y11.79%
EPS Next 5Y1.81%
Revenue Next Year105.57%
Revenue Next 2Y-25.71%
Revenue Next 3Y0.15%
Revenue Next 5Y18.81%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
ADAP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADAP. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.76%
EPS Next 3Y11.79%
5. Dividend
5.1 Amount
ADAP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ADAPTIMMUNE THERAPEUTICS-ADR
NASDAQ:ADAP (11/21/2024, 8:10:45 PM)
After market: 0.625 -0.01 (-1.82%)0.6366
-0.03 (-4.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap162.81M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.54% | ||
| ROE | -75.3% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.09 | ||
| Quick Ratio | 3.09 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)40.99%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y40.09%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)99.89%
Revenue growth 3Y147.83%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y